Since 2000, CONCEPT HEIDELBERG creates the FDA Warning Letter Report on
a yearly basis. In this news we present our systematic analysis of the findings
mentioned in the warning letters issued by FDA in the past Fiscal Year
2003.
If one counts the citations of the individual paragraphs of 21 CFR
(Code of Federal Regulations) Part 211 in the FDA warning letters, one gets
an overview of the principal deficiencies found by FDA representatives
during inspections.
For the Fiscal Year 2003 (Oct. 2002 till Sept. 2003) we have finalised
the analysis of all 42 warning letters citing the paragraphs of Part 211.
Sorted by frequency, the deviations can be represented by the following
graph:

The following table shows the exact titles of the paragraphs as well as
their assignment to the individual systems observed by FDA according to
its system-based inspection approach, which became official in February
2002 (see our GMP
News of 21 July 2003).
|
CFR
Paragraph |
Exact
Title |
Number
of Citations (Number of
Citations in FY 02) |
System |
|
211.100 |
Written procedures; deviations
Subpart F – Production and Process Controls |
25
(32) |
Quality System |
|
211.165 |
Testing and release for distribution
Subpart I – Laboratory Controls |
24
(22) |
Quality System + Laboratory Control System |
|
211.22 |
Responsibilities of quality control unit
Subpart B – Organization and Personnel |
18
(21) |
Quality System |
|
211.192 |
Production record review
Subpart J – Records and Reports |
18
(21) |
Quality System |
|
211.188 |
Batch production and control records
Subpart J – Records and Reports |
17
(20) |
Production System |
|
211.68 |
Automatic, mechanical, and electronic equipment
Subpart D – Equipment |
16
(8) |
Facilities and Equipment System |
|
211.160 |
General requirements
Subpart I – Laboratory Controls |
16
(22) |
Quality System + Laboratory Control System |
|
211.84 |
Testing and approval or rejection of components, drug product
containers, and closures
Subpart E – Control of Components and Drug Product Containers
and Closures |
15 (11) |
Materials System |
|
211.25 |
Personnel qualifications
Subpart B – Organization and Personnel |
14 (15) |
Quality System |
|
211.130 |
Packaging and labelling operations
Subpart G – Packaging and Labeling Control |
11
(7) |
Packaging and Labeling System |
|
211.186 |
Master production and control records
Subpart J – Records and Reports |
11
(7) |
Production System |
|
211.166 |
Stability Testing
Subpart I – Laboratory Controls |
9
(19) |
Laboratory Control System |
|
211.194 |
Laboratory records
Subpart J – Records and Reports |
9 (10) |
Laboratory Control System |
|
211.67 |
Equipment cleaning and maintenance
Subpart D – Equipment |
8 (21) |
Facilities and Equipment System |
|
211.110 |
Sampling and testing of in-process materials and drug products
Subpart F – Production and Process Controls |
8
(14) |
Production System |
|
211.122 |
Materials examination and usage criteria
Subpart G – Packaging and Labeling Control |
8 (8) |
Packaging and Labeling System |
|
211.125 |
Labeling issuance
Subpart G – Packaging and Labeling Control |
8
(3) |
Packaging and Labeling System |
|
211.198 |
Complaint files
Subpart J – Records and Reports |
8
(10) |
Quality System |
From this compilation, it becomes clear that deficiencies in the
quality system were the most frequent ones. As in the past year, the list
is headed by § 211.100, which refers to the creation, approval and
handling of written procedures in the production area and to the handling
of deviations (see our GMP
News of 2 April 2004; the analysis given in that news relates to the
calendar year 2002, not to the fiscal year). The findings referred to the
fact that there were no written procedures or that the existing procedures
were not followed - failures ascribed to the Quality Unit, just as in the
fields "Testing and Release for Distribution"
(211.165) and "Production Record Review" (211.192). Another
thing often criticised by the FDA was the QU's failure to carry out its
responsibilities and duties in an appropriate way.
As it was to be expected, the image of the higher positions of the top
ten deficiencies found in FY 2003 does not differ much from that of FY
2002. According to the system-based inspection approach, the FDA takes an
especially critical look at the quality system in every inspection.
In contrast, there was a great increase in findings concerning the
facilities and equipment system with regard to the qualification,
validation and calibration of production equipment (211.68) - as well as
in the packaging and labeling system with regard to the handling and
control of labels (211.125).
The number of observations concerning "Equipment Cleaning and
Maintenance" (211.67) and "Stability Testing" (211.166) has
fallen significantly; however, even if less frequent, these topics are
still to be found among the top ten.
Generally, the analysis of warning letters provides valuable clues to
the preparation of FDA inspections. One of the most important tasks to be
fulfilled prior to an FDA visit is to check the quality system for
possible gaps and to close them. As the other systems intersect with the
quality system in several points, this approach should prove to be very
efficient.
Our analyses result in data collections containing the precise
descriptions of the findings in question. From now on, we will publish
extracts of this very comprehensive data collection, which will deal with
individual deviations from the top-ten list. You can see a sample page of
the data collection if you click here.
For
the members of the European Compliance Academy, we have made available the
tables for the top 3 deviations in the members area (see item in the top
menu).